a randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving...

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte

globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for

Blood and Marrow Transplantation

by André Tichelli, Hubert Schrezenmeier, Gérard Socié, Judith Marsh, Andrea Bacigalupo, Ulrich Dührsen, Anke Franzke, Michael Hallek, Eckhard Thiel, Martin Wilhelm, Britta Höchsmann, Alain Barrois, Kim Champion, and Jakob R. Passweg

BloodVolume 117(17):4434-4441

April 28, 2011

©2011 by American Society of Hematology

Six-year OS rate in patients with SAA treated with ATG/CSA with or without G-CSF.

André Tichelli et al. Blood 2011;117:4434-4441

©2011 by American Society of Hematology

OS and EFS rates.

André Tichelli et al. Blood 2011;117:4434-4441

©2011 by American Society of Hematology

Response rates according to the time since randomization.

André Tichelli et al. Blood 2011;117:4434-4441

©2011 by American Society of Hematology

Evolution of neutrophil counts during the first year in patients treated with ATG and CSA with and without G-CSF.

André Tichelli et al. Blood 2011;117:4434-4441

©2011 by American Society of Hematology

Survival of patients randomly assigned to receive G-CSF with neutrophil counts ≥ 0.50 × 109/L (blue) at day 30 compared with patients with neutrophil counts < 0.50 × 109/L (green).

André Tichelli et al. Blood 2011;117:4434-4441

©2011 by American Society of Hematology